Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 11, 2016 12:13 PM ET

Biotechnology

Company Overview of IGXBio, Inc.

Company Overview

IGXBio, Inc., a biotechnology company, develops DNA immunotherapies for HIV infection. Its DNA immunotherapies reduce dependency on anti-HIV drug cocktails and diminish the emergence of drug-resistant HIV strains. The company offers GenePro (?4SHIVku2), a DNA therapeutic incorporating a DNA composition that yields high levels of gene expression and non-infectious HIV protein production, and induces an antibody and cellular immune response in animal models, including non-human primates. It’s therapeutic DNA vaccine generates viral like particles to allow the body to develop killer T cells and memory T cells related to HIV. IGXBio, Inc. was formerly known as ImmunoGenetix Therapeutics, Inc. Th...

8527 Bluejacket Street

Lenexa, KS 66214

United States

Founded in 2001

Phone:

888-744-9246

Fax:

888-744-9246

Key Executives for IGXBio, Inc.

Chief Executive Officer, President and Director
Compensation as of Fiscal Year 2015.

IGXBio, Inc. Key Developments

IGXBio, Inc. Presents at Redefining Early Stage Investments (RESI) Conference 2016, Jan-12-2016

IGXBio, Inc. Presents at Redefining Early Stage Investments (RESI) Conference 2016, Jan-12-2016 . Venue: Marine's Memorial Club & Hotel, 609 Sutter St, San Francisco, CA 94102, United States.

IGXBio, Inc. Presents at 8th Annual Biotech Showcase Investor Conference 2016, Jan-11-2016 04:00 PM

IGXBio, Inc. Presents at 8th Annual Biotech Showcase Investor Conference 2016, Jan-11-2016 04:00 PM. Venue: Parc 55 San Francisco, 55 Cyril Magnin Street, San Francisco, CA 94102, United States.

Cannabis Science and IGXBio Sign Collaborative Drug Development Deal

Cannabis Science announced that the company has signed a collaborative drug development deal with IGXBio and its GenePro. Both firms will produce joint protocols that explore potential synergistic effects of their respective drug candidates and potential new drug candidate opportunities. IGXBio has a drug called GenePro®, which is already registered with the FDA and has an IND number. This accelerates the process to seek FDA approval in the future. GenePro is aimed at promoting an anti-HIV immune response that facilitates virus control in HIV-infected subjects.

Similar Private Companies By Industry

Company Name Region
Nimbus Therapeutics, Inc. United States
Immunovative Clinical Research, Inc. United States
Arrowhead Madison, Inc. United States
Actis Biologics, Inc. United States
Care Connectors, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact IGXBio, Inc., please visit www.immunogenetix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.